Media headlines about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. iShares NASDAQ Biotechnology Index earned a news impact score of 0.24 on Accern’s scale. Accern also gave press coverage about the financial services provider an impact score of 45.2252150131674 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Mid-Day ETF Update: ETFs, Stocks Return to Positive Territory on Easing Tax Reform Woes, Upbeat Manufacturing Data – Nasdaq (nasdaq.com)
- In The Spotlight: Marinus Pharma – Nasdaq (nasdaq.com)
- Strongbridge Biopharma plc Added to the NASDAQ Biotech Index – Life Pulse Health (lifepulsehealth.com)
- Mid-Day ETF Update: ETFs, Stocks Rally as Dow, S&P 500 Resume Record Highs Ahead of FOMC Rate Decision – Nasdaq (nasdaq.com)
- Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index – Business Wire (press release) (businesswire.com)
iShares NASDAQ Biotechnology Index (NASDAQ IBB) traded up $1.43 during mid-day trading on Friday, reaching $106.60. 3,025,289 shares of the company’s stock were exchanged, compared to its average volume of 3,271,399. iShares NASDAQ Biotechnology Index has a 12 month low of $87.97 and a 12 month high of $114.17.
TRADEMARK VIOLATION NOTICE: “iShares NASDAQ Biotechnology Index (IBB) Earns Daily Coverage Optimism Rating of 0.24” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://stocknewstimes.com/2017/12/15/ishares-nasdaq-biotechnology-index-ibb-earns-daily-coverage-optimism-rating-of-0-24.html.
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.